25 May , 2026 By : Debdeep Gupta
Aurobindo Pharma shares are likely to remain in focus on May 25 after the United States Food and Drug Administration (USFDA) classified the inspection outcome at one of its facilities as “Official Action Indicated” (OAI).
The USFDA conducted an inspection at Unit-I, a formulation manufacturing facility of the company’s wholly owned subsidiary, Eugia Pharma Specialities, located in Kolthur Village, Shameerpet Mandal, Ranga Reddy district, Telangana, between February 16 and February 27, 2026. Following the inspection, the regulator issued four observations to the facility.
Earlier this month, Aurobindo Pharma reported a modest 2% year-on-year increase in Q4FY26 consolidated net profit to ?921 crore, while revenue from operations rose 5.6% to ?8,853 crore. EBITDA increased marginally by 0.5% to ?1,801 crore, although EBITDA margins declined to 20.3% from 21.4% in the corresponding quarter last year.
In addition, the company had announced a share buyback of up to ?800 crore through the tender offer route. The buyback, which opened on April 23 and closes on April 29, was approved by the board on April 6.
Under the proposal, the company planned to repurchase up to 54,23,728 fully paid-up equity shares with a face value of Re 1 each at a buyback price of ?1,475 per share on a proportionate basis.
0 Comment